{"entity":{"id":"nct05287945","kind":"trial","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","aka":[],"tldr":"A phase 1/2 trial of Orellanine in renal cell carcinoma, run by Oncorena AB, now recruiting.","summary":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma is a phase 1/2 interventional study registered as NCT05287945 by Oncorena AB, with 75 participants planned, started 2023-08-04 and due to reach its primary completion in 2027-12-31. Interventions recorded: Orellanine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05287945","url":"https://clinicaltrials.gov/study/NCT05287945"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","clear-cell-rcc","papillary-rcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05287945","phase":"1/2","setting":"A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","sponsor":"Oncorena AB","started":"2023-08-04","startedType":"actual","enrolled":75,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05287945/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}]}}